The latency protein LANA2 from Kaposi's sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation | Zendy

Mariano Estéban | Zendy; María Ángel García | Zendy; Elena Domingo-Gil | Zendy; Javier Arroyo | Zendy; César Nombela | Zendy; Carmen Rivas | Zendy

Open Access

The latency protein LANA2 from Kaposi's sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation

Author(s) -

Mariano Estéban,

María Ángel García,

Elena Domingo-Gil,

Javier Arroyo,

César Nombela,

Carmen Rivas

Publication year - 2003

Publication title -

journal of general virology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.55

H-Index - 167

eISSN - 1465-2099

pISSN - 0022-1317

DOI - 10.1099/vir.0.19014-0

Subject(s) - protein kinase r , biology , interferon , protein kinase a , eif 2 kinase , apoptosis , rnase p , phosphorylation , virology , kinase , antiviral protein , rna silencing , microbiology and biotechnology , mitogen activated protein kinase kinase , rna , cyclin dependent kinase 2 , rna interference , biochemistry , gene

Kaposi's sarcoma-associated herpesvirus (KSHV) uses several strategies to counteract the interferon (IFN) system. In this study, the relationship of the protein LANA2 from KSHV to the IFN-activated protein kinase (PKR) and 2-5A system was analysed. It was found that LANA2 could not abrogate apoptosis or RNA degradation mediated by the 2-5A system. However, expression of LANA2 inhibited apoptosis triggered by PKR. LANA2 also counteracted the PKR-mediated inhibition of protein synthesis and partially blocked PKR-induced phosphorylation of eIF-2alpha. Analysis of PKR-induced activation of caspases 3 and 9 revealed that LANA2 abrogated activation of caspase 3 but not of caspase 9. These findings show that LANA2 is able to interfere with downstream events triggered by PKR. Hence, LANA2 should be considered as a KSHV defence protein against IFN.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research